Veracyte (VCYT) to Release Quarterly Earnings on Wednesday

Veracyte (NASDAQ:VCYT) is expected to issue its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $135.7860 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Veracyte Stock Down 1.8%

Shares of NASDAQ VCYT opened at $35.63 on Monday. Veracyte has a twelve month low of $22.61 and a twelve month high of $50.71. The firm has a market cap of $2.82 billion, a PE ratio of 93.77 and a beta of 1.91. The business has a fifty day simple moving average of $40.47 and a two-hundred day simple moving average of $37.68.

Insider Buying and Selling

In other news, Director Karin Eastham sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $45.45, for a total transaction of $909,000.00. Following the sale, the director directly owned 13,554 shares in the company, valued at $616,029.30. This trade represents a 59.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Rebecca Chambers sold 13,278 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $46.84, for a total value of $621,941.52. Following the transaction, the chief financial officer owned 109,496 shares in the company, valued at $5,128,792.64. This represents a 10.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,299 shares of company stock valued at $2,679,156 in the last ninety days. Company insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Empowered Funds LLC purchased a new stake in Veracyte in the 4th quarter worth $42,000. Smartleaf Asset Management LLC grew its position in shares of Veracyte by 159.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 679 shares during the period. Osaic Holdings Inc. increased its stake in shares of Veracyte by 289.9% during the second quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 893 shares in the last quarter. State of Wyoming acquired a new position in shares of Veracyte during the 4th quarter worth about $81,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of Veracyte during the 4th quarter worth about $110,000.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wall Street Zen upgraded Veracyte from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Veracyte in a research report on Monday, December 29th. Needham & Company LLC boosted their price target on shares of Veracyte from $41.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Zacks Research raised shares of Veracyte from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Guggenheim increased their price objective on shares of Veracyte from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $46.14.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.